Allogeneic islet transplantation

Bibliography

• RICORDI C: Islet transplantation: a brave new world. Diabetes (2003) 52(7):1595-1603.
   PubMed Web of Science ®Google Scholar
• PILEGGI A, ALEJANDRO R, RICORDI C: Islet transplantation: steady progress and current challenges. Curr. Opin. Organ Transplant. (2006) 11(1):7-13.
   Web of Science ®Google Scholar
• SHAPIRO AM, LAKEY JR, RYAN EA et al.: Islet transplantation in seven patients with Type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. (2000) 343(4):230-238.
   PubMed Web of Science ®Google Scholar
• RYAN EA, LAKEY JR, RAJOTTE RV et al.: Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes (2001) 50(4):710-719.
   PubMed Web of Science ®Google Scholar
• RYAN EA, LAKEY JR, PATY BW et al.: Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes (2002) 51(7):2148-2157.
   PubMed Web of Science ®Google Scholar
• MARKMANN JF, DENG S, HUANG X et al.: Insulin independence following isolated islet transplantation and single islet infusions. Ann. Surg. (2003) 237(6):741-749; discussion 9-50.
   PubMed Web of Science ®Google Scholar
• PILEGGI A, RICORDI C, KENYON NS et al.: Twenty years of clinical islet transplantation at the diabetes research institute – University of Miami. Clin. Transplant. (2004):177-204.
   Google Scholar
• RYAN EA, SHANDRO T, GREEN K et al.: Assessment of the severity of hypoglycemia and glycemic lability in Type 1 diabetic subjects undergoing islet transplantation. Diabetes (2004) 53(4):955-962.
   PubMed Web of Science ®Google Scholar
• HERING BJ, KANDASWAMY R, HARMON JV et al.: Transplantation of cultured islets from two-layer preserved pancreases in Type 1 diabetes with anti-CD3 antibody. Am. J. Transplant. (2004) 4(3):390-401.
   PubMed Web of Science ®Google Scholar
• JOHNSON JA, KOTOVYCH M, RYAN EA, SHAPIRO AM: Reduced fear of hypoglycemia in successful islet transplantation. Diabetes Care (2004) 27(2):624-625.
   PubMed Web of Science ®Google Scholar
• FROUD T, RICORDI C, BAIDAL DA et al.: Islet transplantation in Type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am. J. Transplant. (2005) 5(8):2037-2046.
   PubMed Web of Science ®Google Scholar
• RYAN EA, PATY BW, SENIOR PA et al.: Five-year follow-up after clinical islet transplantation. Diabetes (2005) 54(7):2060-2069.
   PubMed Web of Science ®Google Scholar
• HERING BJ, KANDASWAMY R, ANSITE JD et al.: Single-donor, marginal-dose islet transplantation in patients with Type 1 diabetes. JAMA (2005) 293(7):830-835.
   PubMed Web of Science ®Google Scholar
• BARSHES NR, VANATTA JM, MOTE A et al.: Health-related quality of life after pancreatic islet transplantation: a longitudinal study. Transplantation (2005) 79(12):1727-1730.
   PubMed Web of Science ®Google Scholar
• POGGIOLI R, PONTE G, BAIDAL DA et al.: Quality of life after islet transplantation. Diabetes (2005) 54:A86-A.
   Google Scholar
• SHAPIRO AM, RICORDI C, HERING BJ et al.: International trial of the Edmonton protocol for islet transplantation. N. Engl. J. Med. (2006) 355(13):1318-1330.
   PubMed Web of Science ®Google Scholar
• SKYLER JS: Atlas of Diabetes. (3rd Edition). Current Medicine, LLC, Philadelphia, PA, USA (2006).
   Google Scholar
• GEIGER MC, FERREIRA JV, HAFIZ MM et al.: Evaluation of metabolic control using a continuous subcutaneous glucose monitoring system in patients with Type 1 diabetes mellitus who achieved insulin independence after islet cell transplantation. Cell Transplant. (2005) 14(2-3):77-84.
   PubMed Web of Science ®Google Scholar
• NIDDK: National Diabetes Statistics fact sheet: general information and national estimates on diabetes in the United States, 2005. US department of health and human services, National institute of health, Bethseda, MD, USA (2005).
   Google Scholar
• LEROITH D, TAYLOR SI, OLEFSKY JM: Diabetes Mellitus: A Fundamental and Clinical Text. (3rd Edition). Lippincott Williams & Wilkins, Philadelphia, PA, USA (2003).
   Google Scholar
• NO AUTHORS LISTED:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group. N. Engl. J. Med. (1993) 329(14):977-986.
   PubMed Web of Science ®Google Scholar
• HERMAN WH, DASBACH EJ, SONGER TJ, EASTMAN RC: The cost-effectiveness of intensive therapy for diabetes mellitus. Endocrinol. Metab. Clin. North Am. (1997) 26(3):679-695.
   PubMed Web of Science ®Google Scholar
• HERMAN WH, EASTMAN RC: The effects of treatment on the direct costs of diabetes. Diabetes Care (1998) 21(Suppl. 3):C19-C24.
   PubMed Web of Science ®Google Scholar
• CABRERA O, BERMAN DM, KENYON NS, RICORDI C, BERGGREN PO, CAICEDO A: The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc. Natl. Acad. Sci. USA (2006) 103(7):2334-2339.
   PubMed Web of Science ®Google Scholar
• ROBERTSON RP, DAVIS C, LARSEN J, STRATTA R, SUTHERLAND DE: Pancreas and islet transplantation in Type 1 diabetes. Diabetes Care (2006) 29(4):935.
   PubMed Web of Science ®Google Scholar
• RICORDI C, LACY PE, FINKE EH, OLACK BJ, SCHARP DW: Automated method for isolation of human pancreatic islets. Diabetes (1988) 37(4):413-420.
   PubMed Web of Science ®Google Scholar
• LINETSKY E, BOTTINO R, LEHMANN R, ALEJANDRO R, INVERARDI L, RICORDI C: Improved human islet isolation using a new enzyme blend, liberase. Diabetes (1997) 46(7):1120-1123.
   PubMed Web of Science ®Google Scholar
• ALEJANDRO R, STRASSER S, ZUCKER PF, MINTZ DH: Isolation of pancreatic islets from dogs. Semiautomated purification on albumin gradients. Transplantation (1990) 50(2):207-210.
   PubMed Web of Science ®Google Scholar
• LAKE SP, BASSETT PD, LARKINS A et al.: Large-scale purification of human islets utilizing discontinuous albumin gradient on IBM 2991 cell separator. Diabetes (1989) 38(Suppl. 1):143-145.
   PubMed Web of Science ®Google Scholar
• ICHII H, PILEGGI A, MOLANO RD et al.: Rescue purification maximizes the use of human islet preparations for transplantation. Am. J. Transplant. (2005) 5(1):21-30.
   PubMed Web of Science ®Google Scholar
• CONTRERAS JL, ECKSTEIN C, SMYTH CA et al.: Brain death significantly reduces isolated pancreatic islet yields and functionality in vitro and in vivo after transplantation in rats. Diabetes (2003) 52(12):2935-2942.
   PubMed Web of Science ®Google Scholar
• PONTE G, PILEGGI A, MESSINGER S et al.: Toward maximizing the success rate of human islet isolation: influence of donor and isolation factors. Cell Transplant. (2007) 16:595-607.
   PubMed Web of Science ®Google Scholar
• LAKEY JR, WARNOCK GL, RAJOTTE RV et al.: Variables in organ donors that affect the recovery of human islets of langerhans. Transplantation (1996) 61(7):1047-1053.
   PubMed Web of Science ®Google Scholar
• NANO R, CLISSI B, MELZI R et al.: Islet isolation for allotransplantation: variables associated with successful islet yield and graft function. Diabetologia (2005) 48(5):906-912.
   PubMed Web of Science ®Google Scholar
• LEE TC, BARSHES NR, BRUNICARDI FC et al.: Procurement of the human pancreas for pancreatic islet transplantation. Transplantation (2004) 78(3):481-483.
   PubMed Web of Science ®Google Scholar
• KURODA Y, KAWAMURA T, SUZUKI Y, FUJIWARA H, YAMAMOTO K, SAITOH Y: A new, simple method for cold storage of the pancreas using perfluorochemical. Transplantation (1988) 46(3):457-460.
   PubMed Web of Science ®Google Scholar
• RICORDI C, FRAKER C, SZUST J et al.: Improved human islet isolation outcome from marginal donors following addition of oxygenated perfluorocarbon to the cold-storage solution. Transplantation (2003) 75(9):1524-1527.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO S, OKITSU T, IWANAGA Y et al.: Successful islet transplantation from nonheartbeating donor pancreata using modified Ricordi islet isolation method. Transplantation (2006) 82(4):460-465.
   PubMed Web of Science ®Google Scholar
• LAKEY JR, HELMS LM, KIN T et al.: Serine-protease inhibition during islet isolation increases islet yield from human pancreases with prolonged ischemia. Transplantation (2001) 72(4):565-570.
   PubMed Web of Science ®Google Scholar
• ICHII H, WANG X, MESSINGER S et al.: Improved human islet isolation using nicotinamide. Am. J. Transplant. (2006) 6(9):2060-2068.
   PubMed Web of Science ®Google Scholar
• NOGUCHI H, UEDA M, NAKAI Y et al.: Modified two-layer preservation method (M-Kyoto/PFC) improves islet yields in islet isolation. Am. J. Transplant. (2006) 6(3):496-504.
   PubMed Web of Science ®Google Scholar
• KEMPF MC, ANDRES A, MOREL P et al.: Logistics and transplant coordination activity in the GRAGIL Swiss–French multicenter network of islet transplantation. Transplantation (2005) 79(9):1200-1205.
   PubMed Web of Science ®Google Scholar
• ICHII H, SAKUMA Y, PILEGGI A et al.: Shipment of human islets for transplantation. Am. J. Transplant. (2007) 7(4):1010-1020.
   PubMed Web of Science ®Google Scholar
• ALEJANDRO R, MINTZ DH: Experimental and clinical methods of islet transplantation. Transplantation of the Endocrine Pancreas. Elsevier Science BV (1988):217-223.
   Google Scholar
• TZAKIS AG, RICORDI C, ALEJANDRO R et al.: Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 336(8712):402-405.
   PubMed Web of Science ®Google Scholar
• BAIDAL DA, FROUD T, FERREIRA JV, KHAN A, ALEJANDRO R, RICORDI C: The bag method for islet cell infusion. Cell Transplant. (2003) 12(7):809-813.
   PubMed Web of Science ®Google Scholar
• GOSS JA, SOLTES G, GOODPASTOR SE et al.: Pancreatic islet transplantation: the radiographic approach. Transplantation (2003) 76(1):199-203.
   PubMed Web of Science ®Google Scholar
• FROUD T, YRIZARRY JM, ALEJANDRO R, RICORDI C: Use of D-STAT to prevent bleeding following percutaneous transhepatic intraportal islet transplantation. Cell Transplant. (2004) 13(1):55-59.
   PubMed Web of Science ®Google Scholar
• VENTURINI M, ANGELI E, MAFFI P et al.: Technique, complications, and therapeutic efficacy of percutaneous transplantation of human pancreatic islet cells in Type 1 diabetes: the role of US. Radiology (2005) 234(2):617-624.
   PubMed Web of Science ®Google Scholar
• VILLIGER P, RYAN EA, OWEN R et al.: Prevention of bleeding after islet transplantation: lessons learned from a multivariate analysis of 132 cases at a single institution. Am. J. Transplant. (2005) 5(12):2992-2998.
   PubMed Web of Science ®Google Scholar
• HAFIZ MM, FARADJI RN, FROUD T et al.: Immunosuppression and procedure-related complications in 26 patients with Type 1 diabetes mellitus receiving allogeneic islet cell transplantation. Transplantation (2005) 80(12):1718-1728.
   PubMed Web of Science ®Google Scholar
• CASEY JJ, LAKEY JR, RYAN EA et al.: Portal venous pressure changes after sequential clinical islet transplantation. Transplantation (2002) 74(7):913-915.
   PubMed Web of Science ®Google Scholar
• O'CONNELL PJ, HAWTHORNE WJ, HOLMES-WALKER DJ et al.: Clinical islet transplantation in Type 1 diabetes mellitus: results of Australia's first trial. Med. J. Aust. (2006) 184(5):221-225.
   PubMed Web of Science ®Google Scholar
• SASSA M, FUKUDA K, FUJIMOTO S et al.: A single transplantation of the islets can produce glycemic stability and reduction of basal insulin requirement. Diabetes Res. Clin. Pract. (2006) 73(3):235-240.
   PubMed Web of Science ®Google Scholar
• ALEJANDRO R, LEHMANN R, RICORDI C et al.: Long-term function (6 years) of islet allografts in Type 1 diabetes. Diabetes (1997) 46(12):1983-1989.
   PubMed Web of Science ®Google Scholar
• LAKEY JRT, KIN T, WARNOCK GL et al.: Long-term graft function after allogeneic islet transplantation. Cell Transplant. (2007) 16(4):441-446.
   PubMed Web of Science ®Google Scholar
• RICKELS MR, SCHUTTA MH, MARKMANN JF, BARKER CF, NAJI A, TEFF KL: β-cell function following human islet transplantation for Type 1 diabetes. Diabetes (2005) 54(1):100-106.
   PubMed Web of Science ®Google Scholar
• PATY BW, RYAN EA, SHAPIRO AM, LAKEY JR, ROBERTSON RP: Intrahepatic islet transplantation in Type 1 diabetic patients does not restore hypoglycemic hormonal counterregulation or symptom recognition after insulin independence. Diabetes (2002) 51(12):3428-3434.
   PubMed Web of Science ®Google Scholar
• RICKELS MR, SCHUTTA MH, MUELLER R et al.: Glycemic thresholds for activation of counterregulatory hormone and symptom responses in islet transplant recipients. J. Clin. Endocrinol. Metab. (2007) 92(3):873-879.
   PubMed Web of Science ®Google Scholar
• POGGIOLI R, FARADJI RN, PONTE G et al.: Quality of life after islet transplantation. Am. J. Transplant. (2006) 6(2):371-378.
   PubMed Web of Science ®Google Scholar
• FIORINA P, FOLLI F, ZERBINI G et al.: Islet transplantation is associated with improvement of renal function among uremic patients with Type I diabetes mellitus and kidney transplants. (2003):2150-2158.
   Google Scholar
• VENTURINI M, FIORINA P, MAFFI P et al.: Early increase of retinal arterial and venous blood flow velocities at color doppler imaging in brittle Type 1 diabetes after islet transplant alone. Transplantation (2006) 81(9):1274-1277.
   PubMed Web of Science ®Google Scholar
• LEE TC, BARSHES NR, O'MAHONY CA et al.: The effect of pancreatic islet transplantation on progression of diabetic retinopathy and neuropathy. Transplant. Proc. (2005) 37(5):2263-2265.
   PubMed Web of Science ®Google Scholar
• ALEJANDRO R, MINTZ DH, NOEL J et al.: Islet cell transplantation in Type I diabetes mellitus. Transplant. Proc. (1987) 19(1 Part 3):2359-2361.
   PubMed Web of Science ®Google Scholar
• SCHARP D, LACY P, RICORDI C et al.: Human islet transplantation in patients with Type I diabetes. Transplant. Proc. (1989) 21(1 Part 3):2744-2745.
   PubMed Web of Science ®Google Scholar
• ALEJANDRO R, RUSSELL E, KYRIAKIDES G, MILLER J, MINTZ DH: Islet cell transplantation in patients with Type I diabetes mellitus. Diabetes (1986) 35(S1):A139.
   PubMed Web of Science ®Google Scholar
• SCHARP DW, LACY PE, SANTIAGO JV et al.: Insulin independence after islet transplantation into Type I diabetic patient. Diabetes (1990) 39(4):515-518.
   PubMed Web of Science ®Google Scholar
• SCHARP DW, LACY PE, SANTIAGO JV et al.: Results of our first nine intraportal islet allografts in Type 1, insulin-dependent diabetic patients. Transplantation (1991) 51(1):76-85.
   PubMed Web of Science ®Google Scholar
• MINTZ DH, ALEJANDRO R, MILLER J: Human islet transplantation; the University of Miami experience. In: Transplantation of the Endocrine Pancreas in Diabetes Mellitus. Van Schilfgaarde R, Hardy MA (Eds), Elsevier Science (1988):234.
   Google Scholar
• NAJARIAN JS, SIMMONS RL: The clinical use of antilymphocyte globulin. N. Engl. J. Med. (1971) 285(3):158-166.
   PubMed Web of Science ®Google Scholar
• HERING BJ, BRETZEL RG, HOPT UT et al.: New protocol toward prevention of early human islet allograft failure. Transplant. Proc. (1994) 26(2):570-571.
   PubMed Web of Science ®Google Scholar
• SECCHI A, SOCCI C, MAFFI P et al.: Islet transplantation in IDDM patients. Diabetologia (1997) 40(2):225-231.
   PubMed Web of Science ®Google Scholar
• TIBELL A, BRENDEL M, WADSTROM J et al.: Early experience with a long-distance collaborative human islet transplant programme. Transplant. Proc. (1997) 29(7):3124-3125.
   PubMed Web of Science ®Google Scholar
• OBERHOLZER J, TRIPONEZ F, MAGE R et al.: Human islet transplantation: lessons from 13 autologous and 13 allogeneic transplantations. Transplantation (2000) 69(6):1115-1123.
   PubMed Web of Science ®Google Scholar
• BRETZEL RG, BRANDHORST D, BRANDHORST H et al.: Improved survival of intraportal pancreatic islet cell allografts in patients with Type-1 diabetes mellitus by refined peritransplant management. J. Mol. Med. (1999) 77(1):140-143.
   PubMed Web of Science ®Google Scholar
• HERING BJ, RICORDI C: Results, research priorities, and reasons for optimism: islet transplantation for patients with Type I diabetes. Graft (1999) 2:12-27.
   Google Scholar
• MOREL P, KAUFMAN DB, FIELD MJ, LLOVERAS JK, MATAS AJ, SUTHERLAND DE: Detrimental effect of prednisone on canine islet autograft function. Transplant. Proc. (1992) 24(3):1048-1050.
   PubMed Web of Science ®Google Scholar
• RILO HL, CARROLL PB, ZENG YJ, FONTES P, DEMETRIS J, RICORDI C: Acceleration of chronic failure of intrahepatic canine islet autografts by a short course of prednisone. Transplantation (1994) 57(2):181-187.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ LA, LEHMANN R, LUZI L et al.: The effects of maintenance doses of FK506 versus cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation. Transplantation (1999) 68(10):1532-1541.
   PubMed Web of Science ®Google Scholar
• RICORDI C, ZENG YJ, ALEJANDRO R et al.: In vivo effect of FK506 on human pancreatic islets. Transplantation (1991) 52(3):519-522.
   PubMed Web of Science ®Google Scholar
• RICORDI C, STROM TB: Clinical islet transplantation: advances and immunological challenges. Nat. Rev. (2004) 4(4):259-268.
   Google Scholar
• FIRST MR: Posttransplant diabetes mellitus. Transplantation (2003) 75(10):1769.
   PubMedGoogle Scholar
• ROBERTSON P, DAVIS C, LARSEN J, STRATTA R, SUTHERLAND DE: Pancreas transplantation in Type 1 diabetes. Diabetes Care (2004) 27(Suppl. 1):S105.
   PubMedGoogle Scholar
• FRANK A, DENG S, HUANG X et al.: Transplantation for Type I diabetes: comparison of vascularized whole-organ pancreas with isolated pancreatic islets. Ann. Surg. (2004) 240(4):631-643.
   PubMed Web of Science ®Google Scholar
• GOSS JA, GOODPASTOR SE, BRUNICARDI FC et al.: Development of a human pancreatic islet-transplant program through a collaborative relationship with a remote islet-isolation center. Transplantation (2004) 77(3):462-466.
   PubMed Web of Science ®Google Scholar
• GOSS JA, SCHOCK AP, BRUNICARDI FC et al.: Achievement of insulin independence in three consecutive Type 1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet isolation center. Transplantation (2002) 74(12):1761-1766.
   PubMed Web of Science ®Google Scholar
• WARNOCK GL, MELOCHE RM, THOMPSON D et al.: Improved human pancreatic islet isolation for a prospective cohort study of islet transplantation vs best medical therapy in Type 1 diabetes mellitus. Arch. Surg. (2005) 140(8):735-744.
   PubMed Web of Science ®Google Scholar
• LEHMANN R, WEBER M, BERTHOLD P et al.: Successful simultaneous islet-kidney transplantation using a steroid-free immunosuppression: two-year follow-up. Am. J. Transplant. (2004) 4(7):1117-1123.
   PubMed Web of Science ®Google Scholar
• BERNEY T, BUCHER P, MATHE Z et al.: Islet of langerhans allogeneic transplantation at the University of Geneva in the steroid free era in islet after kidney and simultaneous islet-kidney transplantations. Transplant. Proc. (2004) 36(4):1121-1122.
   PubMed Web of Science ®Google Scholar
• DESAI NM, GOSS JA, DENG S et al.: Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity? Transplantation (2003) 76(11):1623-1625.
   PubMed Web of Science ®Google Scholar
• SHAPIRO AM, GALLANT HL, HAO EG et al.: The portal immunosuppressive storm: relevance to islet transplantation? Ther. Drug Monit. (2005) 27(1):35-37.
   PubMed Web of Science ®Google Scholar
• ZHANG N, SU D, QU S et al.: Sirolimus is associated with reduced islet engraftment and impaired β-cell function. Diabetes (2006) 55(9):2429-2436.
   PubMed Web of Science ®Google Scholar
• CANTALUPPI V, BIANCONE L, ROMANAZZI GM et al.: Antiangiogenic and immunomodulatory effects of rapamycin on islet endothelium: relevance for islet transplantation Am. J. Transplant. (2006) 6(11):2601-2611.
   PubMed Web of Science ®Google Scholar
• BUSSIERE CT, LAKEY JR, SHAPIRO AM, KORBUTT GS: The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia (2006) 49(10):2341-2349.
   PubMed Web of Science ®Google Scholar
• HIRSHBERG B, ROTHER KI, DIGON BJ et al.: Benefits and risks of solitary islet transplantation for Type 1 diabetes using steroid-sparing immunosuppression: the national institutes of health experience. Diabetes Care (2003) 26(12):3288-3295.
   PubMed Web of Science ®Google Scholar
• HAFIZ MM, POGGIOLI R, CAULFIELD A et al.: Cytomegalovirus prevalence and transmission after islet allograft transplant in patients with Type 1 diabetes mellitus. Am. J. Transplant. (2004) 4(10):1697-1702.
   PubMed Web of Science ®Google Scholar
• BARSHES NR, LEE TC, BRUNICARDI FC et al.: Lack of cytomegalovirus transmission after pancreatic islet transplantation. Cell Transplant. (2004) 13(7-8):833-838.
   PubMed Web of Science ®Google Scholar
• CURE P, PILEGGI A, FARADJI RN et al.: Cytomegalovirus infection in a recipient of solitary allogeneic islets. Am. J. Transplant. (2006) 6(5 Part 1):1089-1090.
   PubMed Web of Science ®Google Scholar
• CURE P, PILEGGI A, FROUD T et al.: Alterations of the female reproductive system in recipients of islet grafts. Transplantation (2004) 78(11):1576-1581.
   PubMed Web of Science ®Google Scholar
• FROUD T, BAIDAL DA, PONTE G, FERREIRA JV, RICORDI C, ALEJANDRO R: Resolution of neurotoxicity and β-cell toxicity in an islet transplant recipient following substitution of tacrolimus with MMF. Cell Transplant. (2006) 15(7):613-620.
   PubMed Web of Science ®Google Scholar
• PONTE G, BAIDAL DA, ROMANELLI P et al.: Resolution of severe atopic dermatitis after tacrolimus withdrawal. Cell Transplant. (2007) 16(1):23-30.
   PubMed Web of Science ®Google Scholar
• PILEGGI A, CURE PE, MANRIQUE C et al.: Long-term assessment of renal function in patients with Type 1 diabetes recipients of solitary islet allografts. Am. J. Transplant. (2005) 5:276.
   Google Scholar
• SENIOR PA, PATY BW, COCKFIELD SM, RYAN EA, SHAPIRO AM: Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am. J. Transplant. (2005) 5(9):2318-2323.
   PubMed Web of Science ®Google Scholar
• ANDRES A, TOSO C, MOREL P et al.: Impairment of renal function after islet transplant alone or islet-after-kidney transplantation using a sirolimus/tacrolimus-based immunosuppressive regimen. Transpl. Int. (2005) 18(11):1226-1230.
   PubMed Web of Science ®Google Scholar
• SENIOR PA, ZEMAN M, PATY BW, RYAN EA, SHAPIRO AM: Changes in renal function after clinical islet transplantation: four-year observational study. Am. J. Transplant. (2007) 7(1):91-98.
   PubMed Web of Science ®Google Scholar
• MAFFI P, BERTUZZI F, DE TADDEO F et al.: Kidney function after islet transplant alone in Type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy. Diabetes Care (2007) 30(5):1150-1155.
   PubMed Web of Science ®Google Scholar
• RICORDI C, ZENG Y, ALEJANDRO R et al.: Effect of FK 506 on human pancreatic islets following renal subcapsular transplantation in diabetic nude mice. Transplant. Proc. (1992) 24(3):1042.
   PubMed Web of Science ®Google Scholar
• PATY BW, HARMON JS, MARSH CL, ROBERTSON RP: Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. Transplantation (2002) 73(3):353-357.
   PubMed Web of Science ®Google Scholar
• BELL E, CAO X, MOIBI JA et al.: Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes (2003) 52(11):2731-2739.
   PubMed Web of Science ®Google Scholar
• KENYON NS, CHATZIPETROU M, MASETTI M et al.: Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc. Natl. Acad. Sci. USA (1999) 96(14):8132-8137.
   PubMed Web of Science ®Google Scholar
• KENYON NS, FERNANDEZ LA, LEHMANN R et al.: Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes (1999) 48(7):1473-1481.
   PubMed Web of Science ®Google Scholar
• Autoimmunity after islet-cell allotransplantation. N. Engl. J. Med. (2006) 355(13):1397-1399.
   PubMedGoogle Scholar
• SHAPIRO AMJ, RICORDI C, HERING BJ et al.: International trial of the edmonton protocol for islet transplantation. N. Engl. J. Med. (2006) 355(13):1318-1330.
   PubMed Web of Science ®Google Scholar
• FROUD T, BAIDAL DA, PONTE G, FERREIRA JV, RICORDI C, ALEJANDRO R: Resolution of neurotoxicity and β-cell toxicity in an islet transplant recipient following substitution of tacrolimus with MMF. Cell Transplant. (2006) 15(7):613-620.
   PubMed Web of Science ®Google Scholar
• PONTE GM, BAIDAL DA, BICHARA DA et al.: Mycophenalate mofetil-sirolimus maintenance for islet transplantation. Diabetes (2006) 55:A617-A.
   Google Scholar
• JACOBSON PA, GREEN KG, HERING BJ: Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. J. Clin. Pharmacol. (2005) 45(8):901-909.
   PubMed Web of Science ®Google Scholar
• FARADJI RN, GORN L, BAIDAL DA et al.: Remarkable metabolic control and insulin independence after single donor allogeneic islet mransplantation in a patient with Type 1 diabetes under alemtuzumab induction. Diabetes (2006) 55:A616-A617.
   PubMed Web of Science ®Google Scholar
• MCCURRY KR, IACONO A, ZEEVI A et al.: Early outcomes in human lung transplantation with thymoglobulin or campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J. Thorac. Cardiovasc. Surg. (2005) 130(2):528-537.
   PubMed Web of Science ®Google Scholar
• REYES J, MAZARIEGOS GV, ABU-ELMAGD K et al.: Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). Am. J. Transplant. (2005) 5(6):1430-1436.
   PubMed Web of Science ®Google Scholar
• SHAPIRO R, JORDAN ML, BASU A et al.: Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann. Surg. (2003) 238(4):520-525; discussion 525-527.
   PubMed Web of Science ®Google Scholar
• LOPEZ M, CLARKSON MR, ALBIN M, SAYEGH MH, NAJAFIAN N: A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J. Am. Soc. Nephrol. (2006) 17(10):2844-2853.
   PubMed Web of Science ®Google Scholar
• VOLTARELLI JC, COURI CE, STRACIERI AB et al.: Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed Type 1 diabetes mellitus. JAMA (2007) 297(14):1568-1576.
   PubMed Web of Science ®Google Scholar
• VAN DE LINDE P, BOOG PJ, TYSMA OM et al.: Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin. Clin. Exp. Immunol. (2007) 149(1):56-62.
   Google Scholar
• CALNE R, MOFFATT SD, FRIEND PJ et al.: Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation (1999) 68(10):1613-1616.
   PubMed Web of Science ®Google Scholar
• CALNE R, MOFFATT SD, FRIEND PJ et al.: Prope tolerance with induction using campath 1H and low-dose cyclosporin monotherapy in 31 cadaveric renal allograft recipients. Nippon Geka Gakkai Zasshi (2000) 101(3):301-306.
   PubMedGoogle Scholar
• BARTH RN, JANUS CA, LILLESAND CA et al.: Outcomes at 3 years of a prospective pilot study of campath-1H and sirolimus immunosuppression for renal transplantation. Transpl. Int. (2006) 19(11):885-892.
   PubMed Web of Science ®Google Scholar
• BLOOM DD, HU H, FECHNER JH, KNECHTLE SJ: T-lymphocyte alloresponses of campath-1H-treated kidney transplant patients. Transplantation (2006) 81(1):81-87.
   PubMed Web of Science ®Google Scholar
• KNECHTLE SJ, PIRSCH JD, H FECHNER JJ et al.: Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am. J. Transplant. (2003) 3(6):722-730.
   PubMed Web of Science ®Google Scholar
• MAGLIOCCA JF, KNECHTLE SJ: The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl. Int. (2006) 19(9):705-714.
   PubMed Web of Science ®Google Scholar
• BERNEY T, BUHLER LH, MAJNO P, MENTHA G, MOREL P: Immunosuppression for pancreatic islet transplantation. Transplant. Proc. (2004) 36(2 Suppl.):S362-S366.
   PubMed Web of Science ®Google Scholar
• HEROLD KC, GITELMAN SE, MASHARANI U et al.: A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of Type 1 diabetes. Diabetes (2005) 54(6):1763-1769.
   PubMed Web of Science ®Google Scholar
• KEYMEULEN B, VANDEMEULEBROUCKE E, ZIEGLER AG et al.: Insulin needs after CD3-antibody therapy in new-onset Type 1 diabetes. N. Engl. J. Med. (2005) 352(25):2598-2608.
   PubMed Web of Science ®Google Scholar
• CHATENOUD L: CD3-specific antibody-induced active tolerance: from bench to bedside. Nat. Rev. (2003) 3(2):123-132.
   Google Scholar
• CONTRERAS JL, ECKHOFF DE, CARTNER S et al.: Tolerability and side effects of anti-CD3-immunotoxin in preclinical testing in kidney and pancreatic islet transplant recipients. Transplantation (1999) 68(2):215-219.
   PubMed Web of Science ®Google Scholar
• CONTRERAS JL, JENKINS S, ECKHOFF DE et al.: Stable α- and β-islet cell function after tolerance induction to pancreatic islet allografts in diabetic primates. Am. J. Transplant. (2003) 3(2):128-138.
   PubMed Web of Science ®Google Scholar
• CONTRERAS JL, ECKHOFF DE, CARTNER S et al.: Long-term functional islet mass and metabolic function after xenoislet transplantation in primates. Transplantation (2000) 69(2):195-201.
   PubMed Web of Science ®Google Scholar
• BRINKMANN V, PINSCHEWER D, CHIBA K, FENG L: FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol. Sci. (2000) 21(2):49-52.
   PubMed Web of Science ®Google Scholar
• BAUMRUKER T, BILLICH A, BRINKMANN V: FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis. Expert opin. Investig. Drugs (2007) 16(3):283-289.
   PubMed Web of Science ®Google Scholar
• MAKI T, GOTTSCHALK R, MONACO AP: Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice. Transplantation (2002) 74(12):1684-1686.
   PubMed Web of Science ®Google Scholar
• MAKI T, GOTTSCHALK R, OGAWA N, MONACO AP: Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720. Transplantation (2005) 79(9):1051-1055.
   PubMed Web of Science ®Google Scholar
• FU F, HU S, DELEO J et al.: Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720. Transplantation (2002) 73(9):1425-1430.
   PubMed Web of Science ®Google Scholar
• WIJKSTROM M, KENYON NS, KIRCHHOF N et al.: Islet allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD, and FTY720. Transplantation (2004) 77(6):827-835.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ RH: A cell culture model for T lymphocyte clonal anergy. Science (New York, NY) (1990) 248(4961):1349-1356.
   PubMed Web of Science ®Google Scholar
• LENSCHOW DJ, WALUNAS TL, BLUESTONE JA: CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. (1996) 14:233-258.
   PubMed Web of Science ®Google Scholar
• INVERARDI L, RICORDI C: Tolerance and pancreatic islet transplantation. Philos. Trans. R. Soc. Lond. B. Biol. Sci. (2001) 356(1409):759-765.
   PubMed Web of Science ®Google Scholar
• INVERARDI L, KENYON NS, RICORDI C: Islet transplantation: immunological perspectives. Curr. Opin. Immunol. (2003) 15(5):507-511.
   PubMed Web of Science ®Google Scholar
• BALASA B, KRAHL T, PATSTONE G et al.: CD40 ligand–CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J. Immunol. (1997) 159(9):4620-4627.
   PubMed Web of Science ®Google Scholar
• MOLANO RD, BERNEY T, LI H et al.: Prolonged islet graft survival in NOD mice by blockade of the CD40–CD154 pathway of T-cell costimulation. Diabetes (2001) 50(2):270-276.
   PubMed Web of Science ®Google Scholar
• AUERSVALD LA, ROTHSTEIN DM, OLIVEIRA SC et al.: Indefinite islet allograft survival in mice after a short course of treatment with anti-CD45 monoclonal antibodies. Transplantation (1997) 63(9):1355-1358.
   PubMed Web of Science ®Google Scholar
• ROTHSTEIN DM, LIVAK MF, KISHIMOTO K et al.: Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models. J. Immunol. (2001) 166(1):322-329.
   PubMed Web of Science ®Google Scholar
• MOLANO RD, BERNEY T, PILEGGI A et al.: Prolonged survival of allogeneic islet grafts in NOD mice treated with a combination of anti-CD45RB and anti-CD154 antibodies. Transplant. Proc. (2001) 33(1-2):248-249.
   PubMed Web of Science ®Google Scholar
• NICOLLS MR, COULOMBE M, BEILKE J, GELHAUS HC, GILL RG: CD4-dependent generation of dominant transplantation tolerance induced by simultaneous perturbation of CD154 and LFA-1 pathways. J. Immunol. (2002) 169(9):4831-4839.
   PubMed Web of Science ®Google Scholar
• BERNEY T, PILEGGI A, MOLANO RD et al.: The effect of simultaneous CD154 and LFA-1 blockade on the survival of allogeneic islet grafts in nonobese diabetic mice. Transplantation (2003) 76(12):1669-1674.
   PubMed Web of Science ®Google Scholar
• ADAMS AB, SHIRASUGI N, DURHAM MM et al.: Calcineurin inhibitor – free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes (2002) 51(2):265-270.
   PubMed Web of Science ®Google Scholar
• ADAMS AB, SHIRASUGI N, JONES TR et al.: Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J. Immunol. (2005) 174(1):542-550.
   PubMed Web of Science ®Google Scholar
• ZHENG XX, GAO W, DONSKOY E et al.: An antagonist mutant IL-15/Fc promotes transplant tolerance. Transplantation (2006) 81(1):109-116.
   PubMed Web of Science ®Google Scholar
• FERRARI-LACRAZ S, ZANELLI E, NEUBERG M et al.: Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J. Immunol. (2004) 173(9):5818-5826.
   PubMed Web of Science ®Google Scholar
• AKASHI T, NAGAFUCHI S, ANZAI K et al.: Direct evidence for the contribution of B cells to the progression of insulitis and the development of diabetes in non-obese diabetic mice. Int. Immunol. (1997) 9(8):1159-1164.
   PubMed Web of Science ®Google Scholar
• KONDO S, IWATA I, ANZAI K et al.: Suppression of insulitis and diabetes in B cell-deficient mice treated with streptozocin: B cells are essential for the TCR clonotype spreading of islet-infiltrating T cells. Int. Immunol. (2000) 12(7):1075-1083.
   PubMed Web of Science ®Google Scholar
• VENETZ JP, PASCUAL M: New treatments for acute humoral rejection of kidney allografts. Expert Opin. Investig. Drugs (2007) 16(5):625-633.
   PubMed Web of Science ®Google Scholar
• STARZL TE, DEMETRIS AJ, MURASE N, ILDSTAD S, RICORDI C, TRUCCO M: Cell migration, chimerism, and graft acceptance. Lancet (1992) 339(8809):1579-1582.
   PubMed Web of Science ®Google Scholar
• RICORDI C, KARATZAS T, SELVAGGI G et al.: Multiple bone marrow infusions to enhance acceptance of allografts from the same donor. Ann. NY Acad. Sci. (1995) 770:345-350.
   PubMed Web of Science ®Google Scholar
• BUHLER LH, SPITZER TR, SYKES M et al.: Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation (2002) 74(10):1405-1409.
   PubMed Web of Science ®Google Scholar
• SPITZER TR, DELMONICO F, TOLKOFF-RUBIN N et al.: Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation (1999) 68(4):480-484.
   PubMed Web of Science ®Google Scholar
• SAYEGH MH, FINE NA, SMITH JL, RENNKE HG, MILFORD EL, TILNEY NL: Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann. Intern. Med. (1991) 114(11):954-955.
   PubMed Web of Science ®Google Scholar
• FUDABA Y, SPITZER TR, SHAFFER J et al.: Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am. J. Transplant. (2006) 6(9):2121-2133.
   PubMed Web of Science ®Google Scholar
• INVERARDI L, LINETSKY E, PILEGGI A et al.: Targeted bone marrow radioablation with 153Samarium-lexidronam promotes allogeneic hematopoietic chimerism and donor-specific immunologic hyporesponsiveness. Transplantation (2004) 77(5):647-655.
   PubMed Web of Science ®Google Scholar
• ABDELLI S, ANSITE J, RODUIT R et al.: Intracellular stress signaling pathways activated during human islet preparation and following acute cytokine exposure. Diabetes (2004) 53(11):2815-2823.
   PubMed Web of Science ®Google Scholar
• MOBERG L, JOHANSSON H, LUKINIUS A et al.: Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet (2002) 360(9350):2039-2045.
   PubMed Web of Science ®Google Scholar
• PIEMONTI L, LEONE BE, NANO R et al.: Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. Diabetes (2002) 51(1):55-65.
   PubMed Web of Science ®Google Scholar
• MELZI R, PIEMONTI L, NANO R et al.: Donor and isolation variables associated with human islet monocyte chemoattractant protein-1 release. Transplantation (2004) 78(10):1564-1567.
   PubMed Web of Science ®Google Scholar
• MARZORATI S, ANTONIOLI B, NANO R et al.: Culture medium modulates proinflammatory conditions of human pancreatic islets before transplantation. Am. J. Transplant. (2006) 6(11):2791-2795.
   PubMed Web of Science ®Google Scholar
• KLEIN D, BARBE-TUANA F, PUGLIESE A et al.: A functional CD40 receptor is expressed in pancreatic β cells. Diabetologia (2005) 48(2):268-276.
   PubMed Web of Science ®Google Scholar
• BARBE-TUANA FM, KLEIN D, ICHII H et al.: CD40–CD40 ligand interaction activates proinflammatory pathways in pancreatic islets. Diabetes (2006) 55(9):2437-2445.
   PubMed Web of Science ®Google Scholar
• JOHANSSON U, OLSSON A, GABRIELSSON S, NILSSON B, KORSGREN O: Inflammatory mediators expressed in human islets of langerhans: implications for islet transplantation. Biochem. Biophys. Res. Commun. (2003) 308(3):474-479.
   PubMed Web of Science ®Google Scholar
• CHRISTEN U, VON HERRATH MG: IP-10 and Type 1 diabetes: a question of time and location. Autoimmunity (2004) 37(5):273-282.
   Web of Science ®Google Scholar
• MERANI S, TRUONG WW, HANCOCK W, ANDERSON CC, SHAPIRO AM: Chemokines and their receptors in islet allograft rejection and as targets for tolerance induction. Cell Transplant. (2006) 154:295-309.
   Google Scholar
• MATSUDA T, OMORI K, VUONG T et al.: Inhibition of p38 pathway suppresses human islet production of pro-inflammatory cytokines and improves islet graft function. Am. J. Transplant. (2005) 5(3):484-493.
   PubMed Web of Science ®Google Scholar
• ELDOR R, YEFFET A, BAUM K et al.: Conditional and specific NF-κB blockade protects pancreatic β-cells from diabetogenic agents. Proc. Nat. Acad. Sci. USA (2006) 103(13):5072-5077.
   PubMed Web of Science ®Google Scholar
• NOGUCHI H, NAKAI Y, MATSUMOTO S et al.: Cell permeable peptide of JNK inhibitor prevents islet apoptosis immediately after isolation and improves islet graft function. Am. J. Transplant. (2005) 5(8):1848-1855.
   PubMed Web of Science ®Google Scholar
• FORNONI A, COBIANCHI L, SANABRIA NY et al.: The L-isoform but not D-isoforms of a JNK inhibitory peptide protects pancreatic β-cells. Biochem. Biophys. Res. Commun. (2007) 354(1):227-233.
   PubMed Web of Science ®Google Scholar
• PILEGGI A, FENJVES ES, KLEIN D, RICORDI C, PASTORI RL: Protecting pancreatic β-cells. IUBMB Life (2004) 56(7):387-394.
   PubMed Web of Science ®Google Scholar
• EMAMAULLEE JA, STANTON L, SCHUR C, SHAPIRO AM: Caspase inhibitor therapy enhances marginal mass islet graft survival and preserves long term function in islet transplantation. Diabetes (2007) 56(5):1289-1298.
   Google Scholar
• MONTOLIO M, TELLEZ N, BIARNES M, SOLER J, MONTANYA E: Short-term culture with the caspase inhibitor z-VAD.fmk reduces β cell apoptosis in transplanted islets and improves the metabolic outcome of the graft. Cell Transplant. (2005) 14(1):59-65.
   PubMed Web of Science ®Google Scholar
• POGGIOLI R, MOLANO RD, PILEGGI A, ZAHR E, RICORDI C, INVERARDI L: Improved islet graft function by selective inhibition of COX-2. Cell Transplant. (2003) 12(2):141.
   Google Scholar
• PILEGGI A, MOLANO RD, BERNEY T et al.: Heme oxygenase-1 induction in islet cells results in protection from apoptosis and improved in vivo function after transplantation. Diabetes (2001) 50(9):1983-1991.
   PubMed Web of Science ®Google Scholar
• PILEGGI A, MOLANO RD, BERNEY T et al.: Prolonged allogeneic islet graft survival by protoporphyrins. Cell Transplant. (2005) 14(2-3):85-96.
   PubMed Web of Science ®Google Scholar
• FENJVES ES, OCHOA MS, GAY-RABINSTEIN C et al.: Adenoviral gene transfer of erythropoietin confers cytoprotection to isolated pancreatic islets. Transplantation (2004) 77(1):13-18.
   PubMed Web of Science ®Google Scholar
• YANG Z, CHEN M, ELLETT JD, CARTER JD, BRAYMAN KL, NADLER JL: Inflammatory blockade improves human pancreatic islet function and viability. Am. J. Transplant. (2005) 5(3):475-483.
   PubMedGoogle Scholar
• YANG Z, CHEN M, ELLETT JD, FIALKOW LB, CARTER JD, NADLER JL: The novel anti-inflammatory agent lisofylline prevents autoimmune diabetic recurrence after islet transplantation. Transplantation (2004) 77(1):55-60.
   PubMed Web of Science ®Google Scholar
• SONG S, MORGAN M, ELLIS T et al.: Sustained secretion of human α-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc. Natl. Acad. Sci. USA (1998) 95(24):14384-14388.
   PubMed Web of Science ®Google Scholar
• SONG S, GOUDY K, CAMPBELL-THOMPSON M et al.: Recombinant adeno-associated virus-mediated α-1 antitrypsin gene therapy prevents Type I diabetes in NOD mice. Gene Ther. (2004) 11(2):181-186.
   PubMed Web of Science ®Google Scholar
• LEWIS EC, SHAPIRO L, BOWERS OJ, DINARELLO CA: α1-Antitrypsin monotherapy prolongs islet allograft survival in mice. Proc. Natl. Acad. Sci. USA (2005) 102(34):12153-12158.
   PubMed Web of Science ®Google Scholar
• LU Y, CHOI YK, CAMPBELL-THOMPSON M et al.: Therapeutic level of functional human α-1 antitrypsin (hAAT) secreted from murine muscle transduced by adeno-associated virus (rAAV1) vector. J. Gene Med. (2006) 8(6):730-735.
   PubMed Web of Science ®Google Scholar
• LU Y, TANG M, WASSERFALL C et al.: α1-Antitrypsin gene therapy modulates cellular immunity and efficiently prevents Type 1 diabetes in nonobese diabetic mice. Hum. Gene Ther. (2006) 17(6):625-634.
   PubMed Web of Science ®Google Scholar
• ZHANG B, LU Y, CAMPBELL-THOMPSON M et al.: α1-Antitrypsin protects β-cells from apoptosis. Diabetes (2007) 56(5):1316-1323.
   PubMed Web of Science ®Google Scholar
• GEIGER M, FERREIRA J, BAIDAL D et al.: Use of continuous glucose monitoring system in the evaluation of metabolic control in patients with Type I diabetes mellitus after islet cell transplant. Diabetes (2003) 52:A94-A.
   Google Scholar
• ICHII H, INVERARDI L, PILEGGI A et al.: A novel method for the assessment of cellular composition and β-cell viability in human islet preparations. Am. J. Transplant. (2005) 5(7):1635-1645.
   PubMed Web of Science ®Google Scholar
• GOSS JA, BRUNICARDI FC, FELICIANO S et al.: Achievement of insulin independence via pancreatic islet transplantation using a remote islet isolation center: a first year review. Transplantation (2003) 76(4):S22-S23.
   Google Scholar
• BERMAN DM, CABRERA O, KENYON NM et al.: Interference with tissue factor prolongs intrahepatic islet allograft survival in a nonhuman primate marginal mass model. Transplantation (2007) 84(3):308-315.
   PubMed Web of Science ®Google Scholar
• CAMPBELL PM, SALAM A, RYAN EA et al.: Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. Am. J. Transplant. (2007) 7(5):1242-1248.
   PubMed Web of Science ®Google Scholar
• CARDANI R, BAIDAL DA, PILEGGI A et al.: Risk of post-transplant allosensitization in clinical islet allograft recipients. Am. J. Transplant. (2007) 7(S2):205.
   Google Scholar
• PILEGGI A, MOLANO RD, RICORDI C et al.: Reversal of diabetes by pancreatic islet transplantation into a subcutaneous, neovascularized device. Transplantation (2006) 81(9):1318-1324.
   PubMed Web of Science ®Google Scholar
• KIN T, KORBUTT GS, RAJOTTE RV: Survival and metabolic function of syngeneic rat islet grafts transplanted in the omental pouch. Am. J. Transplant. (2003) 3(3):281-285.
   PubMed Web of Science ®Google Scholar
• CHAFFANJON PC, KENYON NM, RICORDI C, KENYON NS: Omental anatomy of non-human primates. Surg. Radiol. Anat. (2005) 27(4):287-291.
   PubMed Web of Science ®Google Scholar
• WEBER CJ, HARDY MA, PI-SUNYER F, ZIMMERMAN E, REEMTSMA K: Tissue culture preservation and intramuscular transplantation of pancreatic islets. Surgery (1978) 84(1):166-174.
   PubMed Web of Science ®Google Scholar
• RAFAEL E, TIBELL A, SEVANDAHL L et al.: Islet autotransplantation after total pancreatectomy – a case report for a 7 year old child. Pediatr. Transplant. (2007) 11:102.
   Google Scholar
• CARDANI R, PILEGGI A, RICORDI C et al.: Allosensitization of islet allograft recipients. Transplantation (2007) (In Press).
   Google Scholar
• HUSSAIN MA, THEISE ND: Stem-cell therapy for diabetes mellitus. Lancet (2004) 364(9429):203-205.
   PubMed Web of Science ®Google Scholar
• DOMINGUEZ-BENDALA J, RICORDI C: Stem cell plasticity and tissue replacement. Cell Transplant. (2005) 14(7):423-425.
   PubMed Web of Science ®Google Scholar
• DE COPPI P, BARTSCH G Jr, SIDDIQUI MM et al.: Isolation of amniotic stem cell lines with potential for therapy. Nat. Biotechnol. (2007) 25(1):100-106.
   PubMed Web of Science ®Google Scholar
• KARNIELI O, IZHAR-PRATO Y, BULVIK S, EFRAT S: Generation of insulin-producing cells from human bone marrow mesenchymal stem cells by genetic manipulation. Stem Cells (2007) (In Press).
   PubMedGoogle Scholar
• ZHAO Y, HUANG Z, LAZZARINI P, WANG Y, DI A, CHEN M: A unique human blood-derived cell population displays high potential for producing insulin. Biochem. Biophys. Res. Commun. (2007) 360(1):205-211.
   PubMed Web of Science ®Google Scholar
• SEEBERGER KL, DUFOUR JM, SHAPIRO AM, LAKEY JR, RAJOTTE RV, KORBUTT GS: Expansion of mesenchymal stem cells from human pancreatic ductal epithelium. Lab. Investig. J. Tech. Methods Pathol. (2006) 86(2):141-153.
   PubMed Web of Science ®Google Scholar
• OUZIEL-YAHALOM L, ZALZMAN M, ANKER-KITAI L et al.: Expansion and redifferentiation of adult human pancreatic islet cells. Biochem. Biophys. Res. Commun. (2006) 341(2):291-298.
   PubMed Web of Science ®Google Scholar
• LINNING KD, TAI MH, MADHUKAR BV et al.: Redox-mediated enrichment of self-renewing adult human pancreatic cells that possess endocrine differentiation potential. Pancreas (2004) 29(3):E64-E76.
   PubMed Web of Science ®Google Scholar
• SAPIR T, SHTERNHALL K, MEIVAR-LEVY I et al.: Cell-replacement therapy for diabetes: generating functional insulin-producing tissue from adult human liver cells. Proc. Natl. Acad. Sci. USA (2005) 102(22):7964-7969.
   PubMed Web of Science ®Google Scholar
• ZALZMAN M, ANKER-KITAI L, EFRAT S: Differentiation of human liver-derived, insulin-producing cells toward the β-cell phenotype. Diabetes (2005) 54(9):2568-2575.
   PubMed Web of Science ®Google Scholar
• YAMADA S, YAMAMOTO Y, NAGASAWA M, HARA A, KODERA T, KOJIMA I: In vitro transdifferentiation of mature hepatocytes into insulin-producing cells. Endocr. J. (2006) 53(6):789-795.
   PubMed Web of Science ®Google Scholar
• POGGIOLI R, INVERARDI L, RICORDI C: Islet xenotransplantation. Cell Transplant. (2002) 11(2):89-94.
   PubMed Web of Science ®Google Scholar
• CARDONA K, MILAS Z, STROBERT E et al.: Engraftment of adult porcine islet xenografts in diabetic nonhuman primates through targeting of costimulation pathways. Am. J. Transplant. (2007) 7(10):2260-2268.
   PubMed Web of Science ®Google Scholar
• HERING BJ: Islet xenotransplantation – concepts, challenges, and chances. Xenotransplantation (2007) 14(4):369.
   Google Scholar
• ALEJANDRO R, FELDMAN EC, SHIENVOLD FL, MINTZ DH: Advances in canine diabetes mellitus research: etiopathology and results of islet transplantation. J. Am. Vet. Med. Assoc. (1988) 193(9):1050-1055.
   PubMed Web of Science ®Google Scholar
• RICORDI C, ALEJANDRO R, ZENG Y et al.: Human islet isolation and purification from pediatric-age donors. Transplant. Proc. (1991) 23(1 Part 1):783-784.
   PubMed Web of Science ®Google Scholar
• SOCCI C, FALQUI L, DAVALLI AM et al.: Fresh human islet transplantation to replace pancreatic endocrine function in Type 1 diabetic patients. Report of six cases. Acta Diabetol. (1991) 28(2):151-157.
   PubMed Web of Science ®Google Scholar
• GORES PF, NAJARIAN JS, STEPHANIAN E, LLOVERAS JJ, KELLEY SL, SUTHERLAND DE: Insulin independence in Type I diabetes after transplantation of unpurified islets from single donor with 15-deoxyspergualin. Lancet (1993) 341(8836):19-21.
   PubMed Web of Science ®Google Scholar
• MAZZAFERRO V, SOCCI C, REGALIA E et al.: Combined liver and pancreatic islets transplantation in man using cyclosporin immunosuppression. Transpl. Int. (1994) 7(Suppl. 1):S409-S411.
   PubMedGoogle Scholar
• RICORDI C, ANGELICO MC, ALEJANDRO R et al.: Islet transplantation in Type II diabetes. Transplant. Proc. (1995) 27(6):3166.
   PubMed Web of Science ®Google Scholar
• LENISA L, CASTOLDI R, SOCCI C et al.: Cost analysis of kidney-pancreas and kidney-islet transplant. Transplant. Proc. (1995) 27(6):3061-3064.
   PubMed Web of Science ®Google Scholar
• RILO HL, CARROLL PB, SHAPIRO R et al.: Human islet transplantation: results of the first 37 patients. Transplant. Proc. (1995) 27(6):3162-3163.
   PubMed Web of Science ®Google Scholar
• RICORDI C, ALEJANDRO R, ANGELICO MC et al.: Human islet allografts in patients with Type 2 diabetes undergoing liver transplantation. Transplantation (1997) 63(3):473-475.
   PubMed Web of Science ®Google Scholar
• KEYMEULEN B, LING Z, GORUS FK et al.: Implantation of standardized β-cell grafts in a liver segment of IDDM patients: graft and recipients characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft. Diabetologia (1998) 41(4):452-459.
   PubMed Web of Science ®Google Scholar
• PATTOU F, VANTYGHEM MC, NOEL C et al.: Sequential intraportal islet allografts in immunosuppressed Type I diabetic patients: preliminary results. Transplant. Proc. (2000) 32(2):391-392.
   PubMed Web of Science ®Google Scholar
• TIBELL A, BOLINDER J, HAGSTROM-TOFT E et al.: Experience with human islet transplantation in Sweden. Transplant. Proc. (2001) 33(4):2535-2536.
   PubMed Web of Science ®Google Scholar
• BENHAMOU PY, OBERHOLZER J, TOSO C et al.: Human islet transplantation network for the treatment of Type I diabetes: first data from the Swiss-French GRAGIL consortium (1999 – 2000). Groupe de Recherche Rhin Rhjne Alpes Geneve pour la transplantation d'Ilots de Langerhans. Diabetologia (2001) 44(7):859-864.
   PubMed Web of Science ®Google Scholar
• VANTYGHEM MC, HAZZAN M, TOURVIEILLE S et al.: Selection of diabetic patients for islet transplantation. A single-center experience. Diabetes Metab. (2004) 30(5):417-423.
   PubMed Web of Science ®Google Scholar
• TOSO C, BAERTSCHIGER R, MOREL P et al.: Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol. Am. J. Transplant. (2006) 6(5 Part 1):1049-1058.
   PubMed Web of Science ®Google Scholar